Publications in collaboration with researchers from Karmanos Cancer Institute (4)

2024

  1. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

    Journal of Thoracic Oncology, Vol. 19, Núm. 8, pp. 1228-1241

2022

  1. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer

    New England Journal of Medicine, Vol. 386, Núm. 3, pp. 241-251

2017

  1. Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies

    Clinical Lung Cancer, Vol. 18, Núm. 5, pp. 489-496

2013

  1. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

    Cancer Discovery, Vol. 3, Núm. 4, pp. 406-417